Adjuvant treatment of stage IB NSCLC. The problem of stage subset heterogeneity

ONCOLOGY

Volumn 22, Issue 5, 2008, Pages 511-516

  Calhoun, Royce ^a   Jablons, David ^b   Lau, Derick ^a   Gandara, David R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM COMPLEX; UFT; ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; PHARMACOGENOMICS; REVIEW; THORAX RADIOGRAPHY; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; ARTICLE; LUNG TUMOR; MORTALITY; PATHOLOGY; SURVIVAL;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; SURVIVAL ANALYSIS;

EID: 50949083304     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Pfannschmidt J, Muley T, Bulzebruck H, et al: Prognostic assessment after surgical resection for non-small cell lung cancer: Experiences in 2083 patients. Lung Cancer 55:371-377, 2007.
2. Mountain CF: Revisions in the international system for staging lung cancer. Chest 111:1710-1717, 1997.
3. Douillard J-Y, Rosell R, De Lena M, et al: Adjuvant vinorelbine plus cisplatin vs observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial. Lancet Oncol 7:719-727, 2006.
4. Padilla J, Calvo V, Penalver JC, et al: Survival and risk model for stage IB non-small cell lung cancer. Lung Cancer 36:43-48, 2002.
5. Mulligan CR, Meram AD, Proctor CD, et al: Lung cancer staging: A case for a new T definition. Ann Thorac Surg 82:220-226, 2006.
6. Jones DR, Daniel TM, Denlinger CE, et al: Stage IB nonsmall cell lung cancers: Are they all the same? Ann Thorac Surg 81:1958-1962, 2006.
7. Goldstraw P, Crowley J, Chansky K, et al: The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2:706-714, 2007.
8. Rami-Porta R, Ball D, Crowley J, et al: The IASLC Lung Cancer Staging Project: Proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2:593-602, 2007.
9. Ou SHI, Zell JA, Ziogas A, et al: Prognostic significance of the non-size based AJCC T2 descriptors: Visceral pleura invasion (VPI), hilar atelectasis or obstructive pneumonitis in stage IB non-small-cell lung cancer (NSCLC) is dependent on tumor size. Chest 133:662-669, 2008.
10. Tsuchiya T, Hashizume S, Akamine S, et al: Upstaging by vessel invasion improves the pathology staging system of non-small cell lung cancer. Chest 132:170-177, 2007.
11. Cerfolio RJ, Bryant AS, Ohja B, et al: The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 130:151-159, 2005.
12. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909, 1995.
13. Wakelee HA, Schiller JH, Gandara DA: Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: Implications for the New Intergroup Trial. Clin Lung Cancer 8:18-21, 2006.
14. Pignon JP, Tribodet H, Scagliotti GV, et al, on behalf of the LACE Collaborative Group: Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients (abstract 7008). J Clin Oncol 24(18S):366s, 2006.
15. Winton T, Livingston R, Johnson D, et al, for the National Cancer Institute of Canada Clinical Trials G-roup and the National Cancer Institute of the United States Intergroup JBR. 10 Trial Investigators: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352:2589-2597, 2005.
16. Strauss GM, Herndon J, Maddaus MA, et al: Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) protocol 9633 (abstract 7019). Presented at the 2004 ASCO Annual Meeting, New Orleans, June 5-8, 2004. Available at www.asco.org/. Accessed March 12, 2008.
17. Hamada C, Ohta M, Wada H, et al: Survival benefit of oral UFT for adjuvant chemotherapy after completely resected non-small-cell lung cancer (abstract 7002). Proc Am Soc Clin Oncol 22:615, 2004.
18. The International Adjuvant Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351-360, 2004.
19. Wakelee H, Dubey S, Gandara D: Optimal adjuvant therapy for non-small cell lung cancer - how to handle stage I disease. Oncologist 12:331-337, 2007.
20. Stewart LA, Burdett S, Tierney JF, et al: Surgery and adjuvant chemotherapy (CT) compared to surgery alone in non-small cell lung cancer (NSCLC): A meta-analysis using individual patient data (IPD) from randomized clinical trials (RCT) (abstract 7552). J Clin Oncol 25(18S):397s, 2007.
21. Strauss GM, Herndon JE, II, Maddaus MA, et al: Adjuvant chemotherapy in stage 1B non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633 (abstract 7007). J Clin Oncol 24(18S):365s, 2006.
22. Kato H, Ichinose Y, Ohta M, et al, for the Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350:1713-1721, 2004.
23. Gandara DR, Kawaguchi T, Crowley JJ, et al: Pharmacogenomic (PG) analysis of Japan-SWOG common arm study in advanced stage non-small cell lung cancer (NSCLC): A model for testing population-related pharmacogenomics (abstract 7500). J Clin Oncol 25(18S):385s, 2007.
24. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006.
25. Potti A, Mukherjee S, Petersen R, et al: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 355:570-580, 2006.
26. Zheng Z, Chen T, Li X, et al: DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356:800-808, 2007.
27. Lord RVN, Brabender J, Gandara D, et al: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8:2286-2291, 2002.
28. Pisters KM, Evans WK, Azzoli CG, et al: Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol 25:5506-5518, 2007.